Drug intelligence / Profile preview

GGT-008

Development stage: Preclinical
Lead developer: Biosyngen
Modality: Cell Therapies

Overview

GGT-008 is a cell therapy drug candidate developed by BioSyngen. It is currently in preclinical development and targets neoplasms, with specific indications including breast cancer, ovarian cancer, and uterine cervical cancer. The precise mechanism of action and molecular target have not been disclosed publicly as of the latest available information. The therapy may also be under investigation for other endocrinology, metabolic diseases, skin, and musculoskeletal diseases[1].

Beyond the preview

Go deeper on GGT-008.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GGT-008.

Explore the full profile